Surrozen, Inc. (NASDAQ: SRZN) is a Healthcare company (Biotechnology) with a market capitalization of $224M. The Maz Rating grades it against the other companies in its sector.
Surrozen, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $29.98, Surrozen, Inc. trades at 21.5x sales. Over the last twelve months it generated about $10M of revenue and a net loss of $324M. It runs a gross margin of 99.4%, an operating margin of -485.4% and a net margin of -3706.4%. It shows return on equity of 228.0%, return on invested capital of -52.4% and a free cash flow yield of -13.7%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 7.56. Over the past 52 weeks the share price ranged from $12.75 to $37.83, with a beta of 0.56.
Surrozen, Inc. does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 4 Buy and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.